세계의 CRISPR 및 Cas 유전자 시장

Global CRISPR and Cas Genes Market to Reach US$13.2 Billion by 2030

The global market for CRISPR and Cas Genes estimated at US$5.1 Billion in the year 2024, is expected to reach US$13.2 Billion by 2030, growing at a CAGR of 17.4% over the analysis period 2024-2030. Kits & Reagents, one of the segments analyzed in the report, is expected to record a 19.0% CAGR and reach US$4.2 Billion by the end of the analysis period. Growth in the Libraries segment is estimated at 18.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 16.3% CAGR

The CRISPR and Cas Genes market in the U.S. is estimated at US$1.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.0 Billion by the year 2030 trailing a CAGR of 16.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 16.2% and 14.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.6% CAGR.

Global CRISPR and Cas Genes Market - Key Trends & Drivers Summarized

Why Is CRISPR Technology Revolutionizing Biotechnology? Exploring the Rise of Gene Editing

The global CRISPR and Cas genes market has seen exponential growth, driven by groundbreaking advancements in genetic engineering, biomedical research, and agricultural biotechnology. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology has emerged as a game-changing tool, enabling precise gene editing with unprecedented accuracy and efficiency. The increasing focus on gene therapy for treating genetic disorders, cancer, and rare diseases has propelled investment in CRISPR-based applications. Additionally, agricultural biotechnology firms are leveraging CRISPR for crop improvement, disease resistance, and enhanced food production efficiency. The expanding field of synthetic biology and the development of personalized medicine have further strengthened market demand, with CRISPR playing a crucial role in targeted genetic modifications.

Which CRISPR Applications Are Leading the Market? A Breakdown of Key Segments

The CRISPR and Cas genes market is segmented into various applications, each catering to specific scientific and medical advancements. Gene therapy remains one of the most promising applications, with CRISPR being used to correct genetic mutations responsible for inherited disorders such as sickle cell anemia and cystic fibrosis. Agricultural biotechnology is another key segment, where CRISPR is revolutionizing crop development by enhancing drought resistance, disease tolerance, and nutritional content. The rise of CRISPR-based diagnostics has also gained traction, particularly in detecting infectious diseases, including COVID-19. Additionally, the field of drug discovery is benefiting from CRISPR’s ability to create genetically engineered cell models, improving pharmaceutical research and development. The development of CRISPR-based biomanufacturing solutions for synthetic biology and industrial applications has further diversified market opportunities.

How Is Innovation Driving the CRISPR Market? The Role of AI, Automation & Ethical Considerations

The CRISPR market is evolving rapidly with continuous innovations in AI-powered gene editing, automation in genetic screening, and ethical advancements in genome modification. AI-driven bioinformatics tools have enhanced CRISPR efficiency, enabling researchers to predict off-target effects and optimize gene-editing accuracy. The development of next-generation Cas proteins, such as Cas12 and Cas13, has expanded CRISPR’s versatility, allowing for RNA-based modifications and improved specificity. Additionally, the automation of CRISPR workflows through robotic lab systems has accelerated research productivity, reducing manual intervention and increasing throughput. Ethical considerations surrounding gene editing, particularly in human germline modifications, have prompted regulatory frameworks and bioethical discussions to ensure responsible research practices. The emergence of CRISPR-based epigenetic editing, which modifies gene expression without altering DNA sequences, has opened new possibilities for treating complex diseases.

What’s Driving the Growth of the CRISPR Market? Key Market Influencers Explained

The growth in the CRISPR and Cas genes market is driven by increasing investment in genetic research, expanding applications in medicine and agriculture, and continuous technological advancements. The rise of precision medicine has fueled demand for CRISPR-based therapies, offering personalized treatment solutions for genetic disorders and cancer. Additionally, government funding and academic research initiatives have accelerated innovation in CRISPR-based drug discovery and disease modeling. The agricultural sector’s growing need for climate-resilient crops has further boosted CRISPR adoption, providing sustainable solutions for food security challenges. The expansion of biotech startups and partnerships between pharmaceutical companies and research institutions has strengthened market competitiveness. However, ethical and regulatory considerations remain a critical factor, influencing the pace of CRISPR commercialization. With ongoing scientific breakthroughs and evolving regulatory landscapes, the global CRISPR and Cas genes market is expected to witness transformative growth, unlocking new possibilities in genetic engineering and personalized healthcare.

SCOPE OF STUDY:

The report analyzes the CRISPR and Cas Genes market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product & Service (Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis, Screening Services); Application (Biomedical Application, Agricultural Application); End-Use (Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 34 Featured) -

• Addgene
• Agilent Technologies
• Beam Therapeutics
• Caribou Biosciences
• Cellectis
• CRISPR Therapeutics
• Editas Medicine
• GenScript
• Horizon Discovery (PerkinElmer)
• Integrated DNA Technologies (IDT)
• Intellia Therapeutics
• Locus Biosciences
• Mammoth Biosciences
• Merck KGaA
• New England Biolabs
• Origene Technologies
• Sangamo Therapeutics
• Synthego Corporation
• Takara Bio Inc.
• Thermo Fisher Scientific

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • CRISPR and Cas Genes - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Increasing Investment in Gene Editing and Biotechnology Research Spurs Growth in CRISPR and Cas Gene Technologies
  • Surge in Precision Medicine Applications Strengthens the Business Case for CRISPR-Based Therapeutics
  • Rising Demand for Genomic Agriculture Drives Adoption of CRISPR and Cas Genes in Crop Improvement
  • Expansion of Clinical Trials and Gene Therapy Development Generates Accelerated Demand for CRISPR-Cas9 Solutions
  • Technological Advancements in CRISPR/Cas Precision and Efficiency Propel Market Growth in Therapeutic Applications
  • Regulatory Advancements and Easing of Gene Editing Guidelines Expands Market Opportunity for CRISPR-Based Products
  • Rising Focus on Hereditary Disease Treatment and Prevention Accelerates Market Adoption of CRISPR Gene Therapy Solutions
  • Increased Public Awareness of Gene Editing Capabilities and Ethics Throws the Spotlight on Transparent and Responsible CRISPR Applications
  • Growing Investment from Venture Capital and Pharma Companies Strengthens the Case for CRISPR as a Mainstream Technology
  • Expansion of Biopharmaceutical Companies Leveraging CRISPR for Drug Discovery and Development Drives Market Growth
  • Rising Global Demand for Sustainable Agricultural Practices Drives Adoption of CRISPR-Cas Genes in Food Production
  • The Need for Rapid and Cost-Effective Diagnostic Tools Accelerates Demand for CRISPR in Point-of-Care Diagnostics
  • Ongoing Advancements in CRISPR Delivery Systems Drive Adoption of CRISPR Technologies in Clinical and Agricultural Markets
  • Increasing Prevalence of Genetic Disorders and Chronic Diseases Propels the Need for CRISPR-Cas9 Solutions in Healthcare
  • Surge in Ethical and Regulatory Debates Over Germline Editing Impacts Market Expansion and Adoption in Certain Regions
  • Integration of CRISPR with Artificial Intelligence for Drug Development and Personalized Medicine Expands Addressable Market Opportunity
  • The Rise of Gene Drives for Environmental and Pest Control Applications Generates New Market Opportunities for CRISPR Technologies
  • Growing Focus on Environmental Sustainability Strengthens the Case for CRISPR in Bioremediation and Waste Treatment
  • Enhanced CRISPR-based Screening and Research Tools Drive Demand for Advanced Genetic Research Solutions
  • The Expansion of Genomic Data Infrastructure and Bioinformatics Strengthens Market Demand for CRISPR and Cas Integration
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World CRISPR and Cas Genes Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World 6-Year Perspective for CRISPR and Cas Genes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Kits & Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 5: World 6-Year Perspective for Kits & Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 6: World Recent Past, Current & Future Analysis for Libraries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 7: World 6-Year Perspective for Libraries by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Design Tool by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World 6-Year Perspective for Design Tool by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 11: World 6-Year Perspective for Antibodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 12: World Recent Past, Current & Future Analysis for Cell Line Engineering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 13: World 6-Year Perspective for Cell Line Engineering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for gRNA Design & Synthesis & Synthesis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World 6-Year Perspective for gRNA Design & Synthesis & Synthesis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Screening Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 17: World 6-Year Perspective for Screening Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 18: World Recent Past, Current & Future Analysis for Biotechnology & Pharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 19: World 6-Year Perspective for Biotechnology & Pharmaceutical Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Academic & Government Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World 6-Year Perspective for Academic & Government Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 22: World Recent Past, Current & Future Analysis for Contract Research Organizations End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 23: World 6-Year Perspective for Contract Research Organizations End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 24: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 25: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Biomedical Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World 6-Year Perspective for Biomedical Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 28: World Recent Past, Current & Future Analysis for Agricultural Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 29: World 6-Year Perspective for Agricultural Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • CRISPR and Cas Genes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 30: USA Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Product & Service - Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 31: USA 6-Year Perspective for CRISPR and Cas Genes by Product & Service - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services for the Years 2025 & 2030
  • TABLE 32: USA Recent Past, Current & Future Analysis for CRISPR and Cas Genes by End-Use - Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA 6-Year Perspective for CRISPR and Cas Genes by End-Use - Percentage Breakdown of Value Sales for Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2025 & 2030
  • TABLE 34: USA Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Application - Biomedical Application and Agricultural Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 35: USA 6-Year Perspective for CRISPR and Cas Genes by Application - Percentage Breakdown of Value Sales for Biomedical Application and Agricultural Application for the Years 2025 & 2030
• CANADA
  • TABLE 36: Canada Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Product & Service - Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 37: Canada 6-Year Perspective for CRISPR and Cas Genes by Product & Service - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services for the Years 2025 & 2030
  • TABLE 38: Canada Recent Past, Current & Future Analysis for CRISPR and Cas Genes by End-Use - Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Canada 6-Year Perspective for CRISPR and Cas Genes by End-Use - Percentage Breakdown of Value Sales for Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2025 & 2030
  • TABLE 40: Canada Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Application - Biomedical Application and Agricultural Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 41: Canada 6-Year Perspective for CRISPR and Cas Genes by Application - Percentage Breakdown of Value Sales for Biomedical Application and Agricultural Application for the Years 2025 & 2030
• JAPAN
  • CRISPR and Cas Genes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 42: Japan Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Product & Service - Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 43: Japan 6-Year Perspective for CRISPR and Cas Genes by Product & Service - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services for the Years 2025 & 2030
  • TABLE 44: Japan Recent Past, Current & Future Analysis for CRISPR and Cas Genes by End-Use - Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Japan 6-Year Perspective for CRISPR and Cas Genes by End-Use - Percentage Breakdown of Value Sales for Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2025 & 2030
  • TABLE 46: Japan Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Application - Biomedical Application and Agricultural Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 47: Japan 6-Year Perspective for CRISPR and Cas Genes by Application - Percentage Breakdown of Value Sales for Biomedical Application and Agricultural Application for the Years 2025 & 2030
• CHINA
  • CRISPR and Cas Genes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 48: China Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Product & Service - Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 49: China 6-Year Perspective for CRISPR and Cas Genes by Product & Service - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services for the Years 2025 & 2030
  • TABLE 50: China Recent Past, Current & Future Analysis for CRISPR and Cas Genes by End-Use - Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: China 6-Year Perspective for CRISPR and Cas Genes by End-Use - Percentage Breakdown of Value Sales for Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2025 & 2030
  • TABLE 52: China Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Application - Biomedical Application and Agricultural Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 53: China 6-Year Perspective for CRISPR and Cas Genes by Application - Percentage Breakdown of Value Sales for Biomedical Application and Agricultural Application for the Years 2025 & 2030
• EUROPE
  • CRISPR and Cas Genes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 54: Europe Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 55: Europe 6-Year Perspective for CRISPR and Cas Genes by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
  • TABLE 56: Europe Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Product & Service - Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Europe 6-Year Perspective for CRISPR and Cas Genes by Product & Service - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services for the Years 2025 & 2030
  • TABLE 58: Europe Recent Past, Current & Future Analysis for CRISPR and Cas Genes by End-Use - Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 59: Europe 6-Year Perspective for CRISPR and Cas Genes by End-Use - Percentage Breakdown of Value Sales for Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2025 & 2030
  • TABLE 60: Europe Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Application - Biomedical Application and Agricultural Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 61: Europe 6-Year Perspective for CRISPR and Cas Genes by Application - Percentage Breakdown of Value Sales for Biomedical Application and Agricultural Application for the Years 2025 & 2030
• FRANCE
  • CRISPR and Cas Genes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 62: France Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Product & Service - Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: France 6-Year Perspective for CRISPR and Cas Genes by Product & Service - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services for the Years 2025 & 2030
  • TABLE 64: France Recent Past, Current & Future Analysis for CRISPR and Cas Genes by End-Use - Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 65: France 6-Year Perspective for CRISPR and Cas Genes by End-Use - Percentage Breakdown of Value Sales for Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2025 & 2030
  • TABLE 66: France Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Application - Biomedical Application and Agricultural Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 67: France 6-Year Perspective for CRISPR and Cas Genes by Application - Percentage Breakdown of Value Sales for Biomedical Application and Agricultural Application for the Years 2025 & 2030
• GERMANY
  • CRISPR and Cas Genes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 68: Germany Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Product & Service - Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Germany 6-Year Perspective for CRISPR and Cas Genes by Product & Service - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services for the Years 2025 & 2030
  • TABLE 70: Germany Recent Past, Current & Future Analysis for CRISPR and Cas Genes by End-Use - Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 71: Germany 6-Year Perspective for CRISPR and Cas Genes by End-Use - Percentage Breakdown of Value Sales for Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2025 & 2030
  • TABLE 72: Germany Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Application - Biomedical Application and Agricultural Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 73: Germany 6-Year Perspective for CRISPR and Cas Genes by Application - Percentage Breakdown of Value Sales for Biomedical Application and Agricultural Application for the Years 2025 & 2030
• ITALY
  • TABLE 74: Italy Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Product & Service - Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Italy 6-Year Perspective for CRISPR and Cas Genes by Product & Service - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services for the Years 2025 & 2030
  • TABLE 76: Italy Recent Past, Current & Future Analysis for CRISPR and Cas Genes by End-Use - Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 77: Italy 6-Year Perspective for CRISPR and Cas Genes by End-Use - Percentage Breakdown of Value Sales for Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2025 & 2030
  • TABLE 78: Italy Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Application - Biomedical Application and Agricultural Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 79: Italy 6-Year Perspective for CRISPR and Cas Genes by Application - Percentage Breakdown of Value Sales for Biomedical Application and Agricultural Application for the Years 2025 & 2030
• UNITED KINGDOM
  • CRISPR and Cas Genes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 80: UK Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Product & Service - Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: UK 6-Year Perspective for CRISPR and Cas Genes by Product & Service - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services for the Years 2025 & 2030
  • TABLE 82: UK Recent Past, Current & Future Analysis for CRISPR and Cas Genes by End-Use - Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 83: UK 6-Year Perspective for CRISPR and Cas Genes by End-Use - Percentage Breakdown of Value Sales for Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2025 & 2030
  • TABLE 84: UK Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Application - Biomedical Application and Agricultural Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 85: UK 6-Year Perspective for CRISPR and Cas Genes by Application - Percentage Breakdown of Value Sales for Biomedical Application and Agricultural Application for the Years 2025 & 2030
• REST OF EUROPE
  • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Product & Service - Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Rest of Europe 6-Year Perspective for CRISPR and Cas Genes by Product & Service - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services for the Years 2025 & 2030
  • TABLE 88: Rest of Europe Recent Past, Current & Future Analysis for CRISPR and Cas Genes by End-Use - Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 89: Rest of Europe 6-Year Perspective for CRISPR and Cas Genes by End-Use - Percentage Breakdown of Value Sales for Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2025 & 2030
  • TABLE 90: Rest of Europe Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Application - Biomedical Application and Agricultural Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 91: Rest of Europe 6-Year Perspective for CRISPR and Cas Genes by Application - Percentage Breakdown of Value Sales for Biomedical Application and Agricultural Application for the Years 2025 & 2030
• ASIA-PACIFIC
  • CRISPR and Cas Genes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Product & Service - Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Asia-Pacific 6-Year Perspective for CRISPR and Cas Genes by Product & Service - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services for the Years 2025 & 2030
  • TABLE 94: Asia-Pacific Recent Past, Current & Future Analysis for CRISPR and Cas Genes by End-Use - Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 95: Asia-Pacific 6-Year Perspective for CRISPR and Cas Genes by End-Use - Percentage Breakdown of Value Sales for Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2025 & 2030
  • TABLE 96: Asia-Pacific Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Application - Biomedical Application and Agricultural Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 97: Asia-Pacific 6-Year Perspective for CRISPR and Cas Genes by Application - Percentage Breakdown of Value Sales for Biomedical Application and Agricultural Application for the Years 2025 & 2030
• REST OF WORLD
  • TABLE 98: Rest of World Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Product & Service - Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Rest of World 6-Year Perspective for CRISPR and Cas Genes by Product & Service - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services for the Years 2025 & 2030
  • TABLE 100: Rest of World Recent Past, Current & Future Analysis for CRISPR and Cas Genes by End-Use - Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 101: Rest of World 6-Year Perspective for CRISPR and Cas Genes by End-Use - Percentage Breakdown of Value Sales for Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2025 & 2030
  • TABLE 102: Rest of World Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Application - Biomedical Application and Agricultural Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 103: Rest of World 6-Year Perspective for CRISPR and Cas Genes by Application - Percentage Breakdown of Value Sales for Biomedical Application and Agricultural Application for the Years 2025 & 2030

IV. COMPETITION